New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
05:32 EDTZGNXZogenix issues statement on Massachusetts Zohydro ban
Zogenix issued the following statement regarding Massachusetts ban on Zohydro: We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication. We believe Governor Patrick's ban on Zohydro ER only serves to unfairly restrict patient access to the only hydrocodone pain reliever available for long-term, daily, severe chronic pain patients who are obtaining relief with short-acting hydrocodone combination products, but who are at risk for potentially fatal liver toxicity due to their daily intake of acetaminophen. Ultimately, the ban on the prescription medication will add to patient suffering in the state. Contrary to some recent media reports, most other opioid medications on the market are both equal to or more potent than Zohydro ER, and all are available in higher strengths per unit-of-use than Zohydro ER. Claims that Zohydro ER is "more powerful" or "more addictive" than other commonly prescribed opioids are not supported by scientific data. Over the last 12 months, more than 360,000 prescriptions for extended-release opioids were dispensed in Massachusetts, and a significant majority did not have FDA-approved abuse deterrent claims. We fail to see how banning the sale of a single new product will achieve the governor's policy objectives when all of the products that are currently part of the epidemic remain available for sale in the state. We are disappointed that today legitimate severe chronic pain patients in Massachusetts received a serious blow in their efforts to find relief for the suffering that affects their, and their families', daily lives. We look forward to engaging with the governor and his representatives to review the safe use measures already in place.
News For ZGNX From The Last 14 Days
Check below for free stories on ZGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
08:56 EDTZGNXOn The Fly: Pre-market Movers
Subscribe for More Information
07:31 EDTZGNXZogenix Zohydro ER demonstrates sustained 12-hour pain relief
Zogenix announced new post-hoc analysis data showing that the indicated 12-hour dose of Zohydro ER, Extended-Release Capsules, CII, provided durable pain relief over the entire dosing interval. This finding is important because a major concern for all extended-release pain medications is the potential for lack of consistent pain relief throughout the entire day, especially at the end of the dosing.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use